Management Sciences for Health to Strengthen Ukraine's Pharmaceutical Sector, Awarded SAFEMed Project
Arlington, VA—September 14, 2017—Management Sciences for Health (MSH) announced today that it has been awarded the Safe, Affordable, and Effective Medicines for Ukrainians (SAFEMed) Project. This five-year, $12.4 million contract funded by US Agency for International Development (USAID)/Ukraine will support reforms in managing medicines through strengthening pharmaceutical sector governance, optimizing pharmaceutical sector finance, and supporting improved availability and use of essential medicines. The project will be led by MSH and joined by partners Overseas Strategic Consulting (OSC) and IC Consulting Ltd. (UK).
“I am pleased that MSH’s leadership and knowledge in pharmaceutical systems strengthening has been recognized with this award,” said Douglas Keene, MSH’s Vice President, Pharmaceuticals and Health Technologies Group. “We look forward to re-establishing MSH’s presence in the Ukraine and, most importantly, helping to strengthen the country’s health system so that it better serves all people, particularly the most vulnerable.”
This award builds on MSH’s experience in the Ukraine through the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) project and its support for the country’s health reforms, which will enable SAFEMed to launch swiftly. SAFEMed will implement a health systems approach to improving access to and use of appropriate quality medicines in collaboration with the Government of Ukraine, civil society organizations, other implementing partners, and the private sector.
MSH and its partners will support the implementation of clear guidelines and standard operating procedures (SOPs) for pharmaceutical sector systems. Building the capacity of the newly established Essential Medicines List (EML) Committee to adopt and institutionalize best practices in health technology assessment (HTA) will create an evidence base to support transparent, sustainable medicines selection and guide other decision making. Other key activities will enable transparent procurement, support implementation of financial reimbursement of essential medicines through a guaranteed benefits package, and introduce innovative and tested approaches to improving supply chain management and appropriate use of medicines.